Collaborative HTA Re-Assessments & Renewals: In close partnership with the EU/INT HEOR team, co-create evidence strategies and deliver analytical packages (e.g., updated network meta-analyses [NMAs], indirect treatment comparisons [ITCs], and mature economic models) required for HTA re-evaluations, conditional reimbursement reviews, and price renegotiations across major global agencies (such as EU JCA, NICE, G-BA, HAS, CADTH). As a vital stakeholder in the Integrated Evidence Generation Plan (IEGP) governance and brand strategy forums, this role translates commercial, access, and policy priorities into methodologically sound evidence generation plans and tangible deliverables—including updated global core economic models, real-world observational studies, patient registries, Global Value Dossiers (GVDs), and US AMCP dossiers.